Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...

PPARγ nuclear receptor ligand activities can span agonism to inverse agonism. Here, the authors use NMR to show how chemical changes within a ligand series shift the receptor’s dynamic ...

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDAGAITHERSBURG, M.D., March 06, 2025 (GLOBE ...

While a gradual loss in muscle strength is a natural part of aging, for many older adults it's more than just feeling a little weaker. Sarcopenia -- a condition affecting nearly half of adults over 80 ...

A variety of antidotes have been reported to treat SSRI-induced sexual dysfunction effectively; however, virtually all the data on these agents are derived from open case reports and case series ...

After hours: March 11 at 4:07:37 PM EDT Loading Chart for ANAB ...